Previous 10 | Next 10 |
DURHAM, N.C., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webc...
2023-09-08 05:11:14 ET Summary Chimerix meets financial expectations during Q2, 2023 earnings call. Investment thesis for Chimerix focuses on its ONC201 study expected to read out in 2026. Company has high risk of loss despite expected $200 million in liquidity by the end of 2...
Patients Treated with ONC201 Demonstrated Median Overall Survival (mOS) of 21.7 Months in the Front-Line Setting, Post Radiation, Versus 12 Months mOS Historical Control ONC201 Treatment Disrupts Key Metabolic and Epigenetic Pathways DURHAM, N.C., Aug. 16, 2023 (GLOBE NEWSWIRE) --...
2023-08-11 06:15:42 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Chimerix (NASDAQ: CMRX ), like most clinical-stage biotech stocks , is without question a high-risk play. Yet in contrast to other biotechs, where high potential rewards can out...
2023-08-05 13:10:06 ET Chimerix, Inc. (CMRX) Q2 2023 Earnings Conference Call August 3, 2023 8:30 AM ET Company Participants Michelle Laspaluto - Vice President of Strategic Planning and Investor Relations Mike Andriole - President and CEO Josh Allen - Chief Tech...
2023-08-03 07:09:20 ET Chimerix press release ( NASDAQ: CMRX ): Q2 GAAP EPS of -$0.21 beats by $0.03 . Revenue of $0.03M (-93.2% Y/Y) misses by $0.24M . Chimerix’s balance sheet at June 30, 2023 included $233.0 million of capital available to fund operat...
– Phase 3 ACTION Study Ongoing with 77 Sites Activated Across 11 Countries; Reiterate First Interim Overall Survival Analysis Expected Early 2025 – – ONC206 Dose Escalation Completion Expected in First Half 2024 – – Capital Available to Fund Oper...
2023-08-02 15:09:24 ET Chimerix ( NASDAQ: CMRX ) is scheduled to announce Q2 earnings results on Thursday, August 3rd, before market open. The consensus EPS Estimate is -$0.24 and the consensus Revenue Estimate is $0.27M (-38.6% Y/Y). Over the last 3 months, EPS estima...
2023-07-30 14:17:20 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Millionaire-maker penny stocks , as you might guess from the title does not represent a universally accessible sector. While these ideas can possibly make you rich, they can just as easily ...
DURHAM, N.C., July 27, 2023 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases, today announced that it will host a live conference call and audio webc...
News, Short Squeeze, Breakout and More Instantly...
Enact Holdings Inc. (ACT) is expected to report $0.99 for Q1 2024 FormFactor Inc. (FORM) is expected to report $0.09 for Q1 2024 SAAB AB - Class B (SAABF) is expected to report for quarter end 2024-03-31 Lumos Pharma Inc. (LUMO) is expected to report $-1.21 for Q1 2024 Axis Capita...
– Dordaviprone (ONC201) ACTION Study Progressing; Reiterates Expectations for Interim Overall Survival (OS) Data in 2025 and Final OS Data in 2026 – – No Dose Limiting Toxicity in ONC206 Phase 1 Studies to Date, Preliminary Phase 1 Safety and Pharmacokinetic (PK) Data...